Central Precocious Puberty
Gonadotropin-releasing hormone (GnRH) agonist Triptodur treats central precocious puberty via intramuscular injection.
Data from a phase 3 clinical trial found that triptorelin achieved positive results in patients age 2 and older with central precocious puberty.
Ovarian cyst and McCune-Albright syndrome were most responsible for the increased risk of non-congenital adrenal hyperplasia gonadotropin-independent precocious puberty.
Long-term treatment with the histrelin implant safely and effectively sustained gonadotropin suppression and improved predicted adult height in central precocious puberty.
Endocrinology Advisor Articles
- Testosterone Use Remains High Among Men With Coronary Artery Disease
- Higher Risk for Venous Thromboembolism With Oral vs Transdermal HRT
- Comparing Osteoporosis Screening, Treatment Strategies in Postmenopausal Women
- Maternal Thyroid Function in Pregnancy Linked to Childhood Risk for Disease
- Primary Characteristics of PCOS Predictive of Obstetric Complications
- ADA's 2019 Standards of Medical Care in Diabetes Focus on Patient-Centered Care
- Sleep Habits Affect Insulin Sensitivity in Adolescents With Overweight, Obesity
- Levothyroxine Associated With Increased Mortality in Patients With Heart Failure
- Head-to-Head Comparison of Professional vs Personal CGM Systems in T1D
- Dual vs Triple Therapy for Metformin Treatment Intensification in Type 2 Diabetes
- Insulin Analogs vs Regular Human Insulin for Type 2 Diabetes
- Diabetic Ketoacidosis May Affect Brain Development in Children With T1D
- Higher Rates of Comorbidities Among Holocaust Survivors
- Population Health Data May Help Identify Patients at Risk for CVD
- Newborn Genomic Sequencing Can Identify Disease Risk